Article
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2015
Kobayashi Yoshihisa, Togashi Yosuke, Yatabe Yasushi, Mizuuchi Hiroshi, Jangchul Park, Kondo Chiaki, Shimoji Masaki, Sato Katsuaki, Suda Kenichi, Tomizawa Kenji, Takemoto Toshiki, Hida Toyoaki, Nishio Kazuto, Mitsudomi Tetsuya
Abstract excerpt
PURPOSE: Lung cancers harboring common EGFR mutations respond to EGFR tyrosine kinase inhibitors (TKI), whereas exon 20 insertions (Ins20) are resistant to them. However, little is known about mutations in exon 18. EXPERIMENTAL DESIGN: Mutational status of lung cancers between 2001 and 2015 was reviewed. Three representative mutations in exon 18, G719A, E709K, and exon 18 deletion (Del18: delE709_T710insD) were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.